Veru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic Cancer

Veru reported positive preclinical data showing that oral sabizabulin had potent anticancer activity in pancreatic cancer cells resistant to daraxonrasib (RASONQUE). The findings support Veru's decision to advance sabizabulin into its planned development program, though the evidence remains preclinical and clinical efficacy has not yet been established.